134 related articles for article (PubMed ID: 23863651)
1. Phase II clinical trial of high-dose toremifene as primary hormone therapy in aromatase inhibitor-resistant breast cancer.
Ogata H; Okamoto Y; Arima Y; Fukushima H; Takeyama H; Yamashita A; Kinoshita M; Suzuki N; Sawada T; Koshida Y; Matsui A; Tachibana A; Nakayama H; Oishi Y; Nogi H; Uchida K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):749-53. PubMed ID: 23863651
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
Gan To Kagaku Ryoho; 2014 Aug; 41(8):965-70. PubMed ID: 25132027
[TBL] [Abstract][Full Text] [Related]
6. [A study of the efficacy of high-dose toremifene in advanced and recurrent breast cancer].
Tokura H; Fujisaki M; Takahashi T; Takigawa Y; Onouchi S; Matsuda K; Hirata A
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1071-3. PubMed ID: 22790041
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
Niikura N; Kimura M; Kobayashi Y; Asahara F; Hayashi K; Shibata S; Shintoku J
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1013-6. PubMed ID: 19542727
[TBL] [Abstract][Full Text] [Related]
8. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
9. [Indoleamine 2,3-dioxygenase activity during toremifene therapy for aromatase inhibitor-resistant metastatic breast cancer].
Sakurai K; Fujisaki S; Nagashima S; Maeda T; Tomita R; Suzuki S; Hara Y; Hirano T; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1286-8. PubMed ID: 25335719
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
11. [A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].
Kurozumi S; Takeo T; Ikeda F; Horiguchi J; Takeyoshi I; Ito H
Gan To Kagaku Ryoho; 2011 Jan; 38(1):93-6. PubMed ID: 21368465
[TBL] [Abstract][Full Text] [Related]
12. [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Sakurai K; Enomoto K; Amano S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2246-8. PubMed ID: 21224536
[TBL] [Abstract][Full Text] [Related]
13. The clinical benefit of high-dose toremifene for metastatic breast cancer.
Koike K; Edo M; Higaki M; Kitahara K; Satou S; Noshiro H
Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
15. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
16. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
17. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
[TBL] [Abstract][Full Text] [Related]
18. Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer.
Hietanen T; Hakala T; Baltina D; Johansson R; Numminen S; Helle L; Valavaara R; Thölix E
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):37-40. PubMed ID: 9165505
[TBL] [Abstract][Full Text] [Related]
19. Toremifene for breast cancer: a review of 20 years of data.
Vogel CL; Johnston MA; Capers C; Braccia D
Clin Breast Cancer; 2014 Feb; 14(1):1-9. PubMed ID: 24439786
[TBL] [Abstract][Full Text] [Related]
20. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
